Pan-Canadian Oncology Drug Review

Pan-Canadian Oncology Drug Review
Name	Pan-Canadian Oncology Drug Review
Formation	2007
Type	Health technology assessment
Headquarters	Ottawa, Ontario
Region served	Canada
Parent organization	CADTH

Pan-Canadian Oncology Drug Review is a Canadian health technology assessment initiative that evaluated oncology pharmaceuticals for public funding decisions. It provided clinical and economic guidance to provincial and territorial drug plans, engaging with manufacturers, clinicians, and patient groups to inform reimbursement recommendations. The Review interacted with federal and provincial frameworks, health agencies, and advisory bodies across Canada.

Overview

The Review operated as part of provincial and territorial pharmaceutical policy networks involving Canadian Agency for Drugs and Technologies in Health, Provincial health ministries, Territorial Health Authorities, Health Canada, Canadian Institutes of Health Research, and Patented Medicine Prices Review Board stakeholders. It produced advice grounded in comparative effectiveness research and health technology assessment, influencing formulary listings and negotiating arrangements through mechanisms linked to the Pan-Canadian Pharmaceutical Alliance and provincial procurement systems. The Review’s outputs interfaced with clinical guideline producers such as Cancer Care Ontario, BC Cancer Agency, Quebec Ministry of Health and Social Services, and specialty societies like the Canadian Cancer Society and the Canadian Association of Medical Oncologists.

History and Development

Established amid 2000s reforms to centralize assessment capacity, the Review emerged from dialogues among provincial premiers, federal ministers, and agencies including Canadian Agency for Drugs and Technologies in Health and the Canadian Strategy for Cancer Control. Its formation paralleled initiatives such as the Pan-Canadian Pharmaceutical Alliance and followed precedents set by international HTA organizations like the National Institute for Health and Care Excellence and the Scottish Medicines Consortium. Early operational links connected the Review to academic partners at institutions such as the University of Toronto, McGill University, University of British Columbia, McMaster University, and Université de Montréal. Over time it adapted methods used by Institut national d'excellence en santé et en services sociaux and by bodies like the Australian Pharmaceutical Benefits Advisory Committee.

Mandate and Scope

Mandated to assess new and existing oncology drugs, the Review’s scope encompassed evaluations requested by provincial drug plans, manufacturers, and clinician groups including Royal College of Physicians and Surgeons of Canada, Canadian Association of Nurses in Oncology, and patient‑advocacy organizations like Canadian Cancer Survivor Network. It addressed indications across malignancies treated in settings aligned with programs at CancerCare Manitoba, Alberta Health Services, Nova Scotia Health Authority, and other provincial cancer agencies. The Review’s remit covered clinical effectiveness, safety, cost‑effectiveness, and implementation considerations relevant to public coverage decisions and negotiated price arrangements under provincial formularies and national procurement collaborations.

Methodology and Review Process

The Review applied systematic review techniques, health economic modeling, and stakeholder input processes comparable to methods used by Institute for Clinical and Economic Review, Health Technology Assessment International, and academic health economics units at University of Calgary and Université Laval. Submissions from pharmaceutical companies were appraised against randomized controlled trials, real‑world evidence from registries like the Canadian Cancer Registry, and outcomes prioritized by clinical practice guidelines from entities such as the National Comprehensive Cancer Network and European Society for Medical Oncology. Expert panels including oncologists from Ottawa Hospital Research Institute and statisticians from Sunnybrook Health Sciences Centre reviewed evidence; cost‑utility analyses employed quality‑adjusted life year frameworks common in HTA. The process incorporated patient input solicited through networks like Canadian Cancer Survivor Network and provincial patient advisory committees.

Governance and Stakeholders

Governance structures linked the Review to the Canadian Agency for Drugs and Technologies in Health and to provincial ministers responsible for health; advisory committees included clinicians from Canadian Association of Medical Oncologists, health economists from Fraser Institute affiliates, and patient representatives from organizations such as Canadian Cancer Survivor Network and regional cancer foundations like BC Cancer Foundation. Industry engagement occurred with multinational manufacturers headquartered in countries represented by organizations like the International Federation of Pharmaceutical Manufacturers & Associations, and negotiation interactions involved procurement groups analogous to the Pan-Canadian Pharmaceutical Alliance.

Impact and Reception

The Review influenced coverage decisions across Canadian jurisdictions, shaping listings in provincial formularies administered by agencies such as Ontario Ministry of Health and Long‑Term Care, Manitoba Health, and Saskatchewan Health Authority. Its recommendations informed price negotiations, sometimes referenced in policy analyses by think tanks like the Canadian Institute for Health Information and in academic literature from institutions such as University of Ottawa and Dalhousie University. Clinicians in oncology practices at tertiary centres including Princess Margaret Cancer Centre and BC Cancer cited Review outputs in multidisciplinary tumour boards and guideline adaptation. Patient groups and provincial ministries acknowledged the Review’s role in standardizing assessment criteria across provinces.

Controversies and Criticisms

Critiques mirrored controversies faced by HTA bodies globally, reflecting tensions reported in debates involving National Institute for Health and Care Excellence, Scottish Medicines Consortium, and Institute for Clinical and Economic Review. Stakeholders challenged aspects of the Review’s approach concerning transparency of confidential price agreements, the handling of surrogate endpoints versus overall survival as debated by European Medicines Agency and Food and Drug Administration reviewers, and perceived delays in accessing therapies noted by patient advocacy groups like Colorectal Cancer Canada and Lymphoma Canada. Academic critics from McMaster University and policy analysts at Fraser Institute raised questions about methodological choices in cost‑effectiveness thresholds and equity across rural services administered by regional health authorities. Disagreements occasionally led provinces to pursue unilateral funding decisions outside the Review’s recommendations.

Category:Health technology assessment